SFDA clears two drugs for China Sky One

China Sky One Medical, a China-based manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products, says that its subsidiary, Heilongjiang Tianlong Pharmaceuticals, has obtained approvals for two new drugs; oxymetazoline HCl nasal drops and taurine eye drops, from the State Food and Drug Administration.

Oxymetazoline is cleared for the treatment of acute and chronic rhinitis, sinusitis and allergic rhinitis and taurine as a therapy for acute and chronic conjunctivitis. The incidences of these diseases in China are extremely high. This is especially true in regions with colder weather as well as coastal regions.

These approvals bring the total number of China Sky One's products for externally used drugs to 49 and the total marketed products to 98,giving the company the most comprehensive pharmaceutical product portfolio in China, it claims. The drugmaker is still aggressively seeking approval for other products with large market potential and by the end of 2008, expects to have a total 38 new drugs submitted to the SFDA.